Based on considerable scientific progress the inhibition of the EMT through the identification of TGF-β antagonists that block both SMAD- and non-SMAD-dependent pathways may be among the most important priority research goal for the prevention of cancer and chronic inflammatory diseases progression. The gene discussed is TGFB1; the disease is cancer.